FDA supplemental approval: Azacitidine (Labeling)

AI Summary

The FDA approved a supplemental labeling change for a generic azacitidine product (ANDA204949) manufactured by Pharmobedient on 2026-06-09. This is an administrative regulatory action updating product labeling for intravenous and subcutaneous azacitidine 100mg/vial formulations.

Plain-language summary

FDA supplemental approval for labeling changes to azacitidine generic product; does not report clinical efficacy or safety data.

Study design

As stated by the source record.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This labeling supplement does not change prescribing indications or introduce new clinical data. Clinicians should review updated product labeling for any changes to administration, safety, or dosing information.

Caveats

• This is a regulatory record, not a clinical trial; no efficacy or safety outcomes reported
• Specific nature of labeling changes not detailed in this record
• No comparative data or clinical trial results provided
• Generic product supplement; relationship to reference product labeling unclear

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.